Skip to main content

Table 4 Efficacy of AC in different subgroups

From: Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

  1,2,5-y OS 1,2,5-y LFFS 1,2,5-y DFFS
CRT-alone CRT-AC p CRT-alone CRT-AC p CRT-alone CRT-AC p
Clinical N stage N0 76.5, 58.8, 52.3 95.0, 81.0, 66.7 0.297 69.3, 69.3, 69.3 95.2, 95.2, 89.6 0.105 94.4, 87.2, 87.2 95.2, 89.6, 89.6 0.777
N1 68.2, 37.9, 23.5 79.0, 33.6, 14.4 0.324 69.7, 58.8, 55.3 62.6, 45.7, 31.3 0.131 68.9, 60.7, 57.3 78.5, 68.3, 53.4 0.377
N2 40.0, 26.7, 0.0 33.0, 0.0, 0.0 0.785 51.9, 0.0, .0.0 33.3, 33.3, 33.3 0.877 80.0, 53.3, 53.3 0.0, 0.0, 0.0 0.942
Clinical M stage M0 71.7, 45.8, 35.5 79.7,57.0, 31.0 0.880 70.0, 61.0, 61.0 70.6, 63.5, 57.1 0.860 79.5, 70.3, 67.5 89.6, 79.4, 79.4 0.191
M1 50.0, 18.2, 4.5 50.0, 18.7, 12.5 0.936 60.6, 44.2, 29.5 67.3, 26.9, 0.0 0.692 52.6, 46.1, 46.1 59.2, 47.4, 47.4 0.792
Clinical TNM stage II 75.3, 43.9,43.9 95.0, 80.0, 55.0 0.208 72.7, 58.2, 58.2 90.0, 90.0, 84.4 0.079 81.6, 74.2, 74.2 95.0, 95.0, 87.1 0.195
III 71.7, 37.9, 33.2 61.1, 38.9, 16.7 0.378 68.8, 51.6, 51.6 59.3, 37.6, 37.6 0.549 61.4, 62.2, 62.2 87.7, 68.2, 56.8 0.598
IVA 69.7, 54.9, 33.8 67.7, 38.7, 23.5 0.651 77.8, 72.9, 72.9 64.2, 59.9, 47.2 0.120 86.7, 76.6, 69.7 86.6, 71.9, 63.9 0.878
short-term response CR 88.5,76.5,58.4 100, 87.5,78.0 0.274 88.0, 79.4, 74.1 95.8, 91.3, 84.2 0.276 84.4, 76.2, 71.1 95.8, 83.3, 74.8 0.590
PR 46.1,17.1,12 60.0, 20.0, 0.0 0.998 55.4, 50.8, 50.8 68.2, 52.8, 33.0 0.954 60.6, 48.6, 48.6 67.9, 55.7, 55.7 0.470
SD 77.4, 36.1,24 56.3, 37.2, 22.3 0.616 65.7, 48.3, 48.3 50.8, 36.9, 31.6 0.277 80.3, 72.3, 72.3 92.8, 86.2, 77.6 0.117
PD 25.0, 0.0, 0.0 33.3, 0.0, 0.0 0.704 33.3, 33.3, 33.3 66.7, 66.7, 66.7 0.642 75.0, 75.0, 75.0 0.0, 0.0, 0.0 0.247
  1. M1: supraclavicular lymph node metastasis